Before concluding this section, it is also important to add that in addition to degrading mutant p53 via downregulation of the mevalonate pathway, there are several other mechanisms by which statins could exert anti-cancer activity (for review, see ref. [90]). The gene discussed is TP53; the disease is cancer.